Olmesartan/Hydrochlorothiazide Stada (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Hydrochlorothiazide Stada, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure reduction beyond what an ARB alone can provide.

GNH USA supplies Olmesartan/Hydrochlorothiazide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Hydrochlorothiazide combines an ARB with a thiazide diuretic to lower blood pressure through complementary mechanisms. - Hypertension: provides additional blood pressure reduction when monotherapy is insufficient. - Resistant hypertension: helps achieve target pressures in patients whose blood pressure remains uncontrolled on multiple agents. - Hypertensive patients with fluid retention: reduces excess fluid volume while blocking angiotensin‑II effects.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance (e.g., hyponatremia) - Pancreatitis

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate baseline creatinine and eGFR. - Electrolytes: check potassium and sodium levels regularly. - Volume status: monitor for signs of dehydration or fluid overload. - Concomitant drugs: review use of other potassium‑sparing agents or NSAIDs. - Pregnancy: avoid use unless clearly needed, as safety is not established. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan/Hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia. - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia. - Lithium: thiazide component may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hypotension and renal dysfunction. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.